IAVI Report has no reviews yet.
Tell people what you think

Year after year, the IAVI Report team is inspired and amazed by the innovative science we get to write about, the personal motivation that drives scientists and advocates toward an HIV vaccine, and the extraordinary commitment of those working tirelessly to end AIDS. This issue, which closes out 2017, features a bit of all those things. There is a Q&A with Thomas Hope of Northwestern University about an effort he co-leads to develop a long-acting, implantable HIV prevention d...evice. There are feature articles on the field’s considerations for planning an HIV vaccine trial in a pediatric population and on the increasing threat of HIV drug resistance. And there is another story about Marianne W. Mureithi, who after completing her studies abroad has returned to Kenya to contribute to HIV prevention research in an area hard hit by the virus. Finally, there is a story about Peter Sands, the newly appointed executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, which has spent billions of dollars raised from international governments to try to stamp out this deadly trio of diseases in places where they are most prevalent. Science, commitment, and motivation in action.

See More
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.

As of 2016 there are 36.7 million people worldwide living with HIV. Roughly half of them are now receiving life-saving antiretroviral therapy. A significant achievement to say the least. But scientists, funders, and HIV prevention advocates who gathered at the New York Academy of Sciences on September 22, just after the close of the United Nations General Assembly meetings in New York City, warned that this progress, while significant, is incomplete and fragile. There were st...ill 1.8 million people newly infected with HIV last year, which is why HIV prevention remains paramount. Newer and better HIV prevention options, particularly those that are longer acting, are still sorely needed, and improved access to existing methods is also critical. We cover both of those topics in this issue, along with an update on the funding situation for HIV R&D, a full research update from the International AIDS Society 2017 conference, and an interview with AIDS vaccine researcher Devin Sok. Click below to read more...

See More
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world.

If a picture is worth a thousand words, then the recently held workshop "Harnessing Novel Imaging Approaches to Guide HIV Prevention and Cure Discoveries" was probably akin to Proust. This two-day meeting featured a slew of interesting pictures of the virus and in this issue we have a curated selection of some of the best images, which are both informative and striking. We also provide a scientific update of data presented at the Keystone Symposium on HIV Vaccines, a profile ...of the cytomegalovirus-based HIV vaccine candidate that is being readied for human clinical trials, and an interview with Michael Osterholm, author of the recently published book "Deadliest Enemy, Our War Against Killer Germs." In this lucid and somewhat terrifying book, Osterholm describes the top infectious disease threats facing the world today and how more science and funding are needed to keep them at bay. Read more in the newest issue of IAVI Report...

See More

The latest issue of IAVI Report marks an important milestone—it ushers the publication into its third decade. It is a testament to the science, which is so dynamic and captivating, that even after 20 years of covering HIV vaccine research there is always more to report on and write about. Some of that scientific work is highlighted here. In this issue, we report on the latest advances from the Conference on Retroviruses and Opportunistic Infections, held this February. We als...o spoke with Mark Connors of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases about the latest and greatest broadly neutralizing antibody, N6, that his lab isolated and what the advances in antibody discovery mean for HIV prevention.

We also describe in depth the Coalition for Epidemic Preparedness Innovations (CEPI), an organization that sprung up in the aftermath of the latest and largest Ebola outbreak and aims to fill the gaps in vaccine development for emerging pathogens that are considered among the top infectious disease threats. CEPI recently appointed its inaugural chief executive officer, Richard Hatchett, whom we spoke with about his plans for the newly formed coalition.

See More

IAVI Report’s final issue of the year offers a comprehensive report on the major findings presented at the HIV Research for Prevention conference held in October. At this meeting, antibodies were a prominent theme. From the trials testing the ability of directly administered broadly neutralizing antibodies to prevent HIV infection to the latest efforts to engineer a series of vaccine immunogens that could induce these powerful proteins, antibodies are fueling scientific devel...opments in many areas. This issue of IAVI Report also features a Q&A with Emilio Emini, director of the HIV program at the Bill & Melinda Gates Foundation. Emini warns that the AIDS response is at a particular crucial juncture—particularly in sub-Saharan Africa where there is a large population of young people about to enter the age range when their susceptibility to contracting HIV is the highest. Emini elaborates on this situation and how it provides the lens through which the Gates Foundation, the world’s largest charitable foundation, views all of its funding decisions. It is within these vulnerable populations that the Centre for the AIDS Programme of Research in South Africa (CAPRISA) is striving to halt the epidemic through a variety of options. This issue profiles their impressive commitment to turning the tide against HIV and tuberculosis.

See More

To be sure, the progress in providing millions of HIV-infected people with life-saving antiretroviral treatment and the progress in developing new prevention strategies was oft discussed at AIDS 2016. But advocates, public health experts, and government officials are far from resting on their laurels. In fact, experts at AIDS 2016 in Durban warned that the hard-won gains against HIV/AIDS are in peril of being lost if financial support isn’t maintained and improved HIV prevent...ion efforts aren’t implemented. In the newest issue of IAVI Report, we provide our complete coverage of AIDS 2016. We also look at how the European Union is hoping to stimulate HIV vaccine research efforts across its partner countries and provide an update on the imminent HVTN 702 trial, the first large-scale vaccine efficacy trial to begin since the results of the RV144 trial in Thailand indicated that a prime-boost vaccine regimen provided a modest 31% protection against HIV infection. Finally, we include an interview with Ugandan physician, public health expert, and former IAVI Board member Alex Coutinho about his long and varied career working in HIV. Read more at the link below...

See More

The August issue of VAX is now live! Featuring a report on the AIDS 2016 conference in Durban last month, as well as a Primer on understanding the rationale for the HVTN 702 trial. Check it out...

Thousands of researchers, advocates, and clinicians gathered in Durban last month for AIDS 2016. Here are the highlights.

When thousands of HIV researchers, clinicians, and advocates descend upon Durban, South Africa, next month the situation will be dramatically different than it was 16 years ago when the International AIDS Conference was held in this coastal city. Then, life-saving antiretroviral drugs were still not widely available in developing countries. But after the 2000 AIDS conference everything changed. A “movement” began, as current President of the International AIDS Society Chris B...eyrer calls it. That movement has resulted in 17 million people receiving antiretroviral therapy. But Beyrer warns against declaring victory too early. In this issue, he talks about the successes in battling HIV/AIDS as well as the multiple challenges that still remain. Also in this issue, a report on dengue and the development of vaccines to fend off this mosquito-borne pathogen and the story of the prolific, young scientist Dan Barouch, whose relentless dedication to all areas of HIV research are helping to propel the quest for a vaccine. Read more by clicking below...

See More

Check out the new issue of VAX, which has a feature on why an AIDS vaccine is still necessary, as well as a full report from the United Nations High-Level Meeting on Ending AIDS.

As we enter the third decade of IAVI Report, we would like to ask for your feedback.

Please take this brief survey. It’s only 10 questions and won’t take long!

IAVI Report is kicking off its 20th year, and as we enter our third decade of covering HIV vaccine research there is still much to report. In the latest issue we discuss the future of HIV vaccine development and the Global HIV Vaccine Enterprise with Executive Director William Snow, provide a full report on the latest news in HIV prevention from this year's Conference on Retroviruses and Opportunistic Infections, and bid farewell to Wayne Koff, IAVI's long-time Chief Science Officer. Click below to read more...

It was 20 years ago this summer that the first issue of IAVI Report was published. That was the same year that IAVI was founded as a product development partnership with an aim to expedite development of an HIV vaccine that was relevant in the parts of the world that were most affected by HIV/AIDS.

As 2015 draws to a close, we are ending the year with stories of inspiration, hope, and progress. These sentiments are captured in an article on the continuing efforts to develop microbicides to prevent HIV infection in women, an interview with Nobel laureate Francoise Barre-Sinoussi who was a co-discoverer of HIV, and the story of the rapid development and testing of Ebola vaccine candidates in response to the world’s worst outbreak to date. While 2014 was marred by the deadliest Ebola epidemic in history, there was great progress this year in developing vaccines meant to prevent another outbreak from escalating out of control or even occurring in the first place. Read more in the latest issue of IAVI Report...

I imagine there are many spectacular perks to being editor of a travel magazine. Trips to exotic destinations, stays in fancy hotels, those sorts of things. Well, one of the best parts of being editor of IAVI Report is sitting down with some of the greatest scientists and policymakers in the field a…

Fantastic perspectives on how to fight HIV in New York, the US and globally! Together we can end AIDS! Let’s make it happen! #WorldAIDSDay #EndAIDSTogether International AIDS Vaccine Initiative Mo Rocca Housing Works Bookstore Cafe GMHC ACLU Nationwide

Paige Bagby added 13 new photos — with Kasheik Paisley and 20 others.

Fantastic perspectives on how to fight HIV in New York, the US and globally! Together we can end AIDS! Share the post. Spread the message. Let’s make it happen! #WorldAIDSDay #EndAIDSTogether International AIDS Vaccine Initiative Mo Rocca Housing Works Bookstore Cafe GMHC ACLU Nationwide

Check out the November issue of VAX, featuring a perspective by human rights activist Tian Johnson on what an HIV vaccine would mean, and a Primer on understanding germinal centers and what scientists are learning about the structures within which antibody-producing cells develop and mature.

Last month in Cape Town, South Africa, scientists from around the world met for the bi-annual HIV Vaccine Trials Network meeting. Human rights activist Tian Johnson was there and writes about what the discovery of an HIV vaccine would mean to him.

For many children around the world vaccines are an unaffordable luxury. But thanks in large part to Gavi, The Vaccine Alliance, that is changing. Over the last 15 years, Gavi has successfully worked in multiple ways to bring life-saving vaccines to the poorest children in the world. In the latest issue of IAVI Report we look at how Gavi works to negotiate lower prices for vaccines in the poorest nations. This issue also features an exclusive interview with Mark Feinberg, who ...stepped into the role of President and Chief Executive Officer of IAVI in early September. Feinberg has vast experience in vaccine research, development, and deployment. Finally, we round out the issue with a commentary piece on the critical role non-human primate studies can and should play in HIV vaccine development, a brief outlining several bold steps taken recently by international agencies that are all meant to slow the spread of HIV/AIDS or eliminate it entirely, and another brief on a recently held symposium on germinal center dynamics and HIV antibody maturation. Read more here:…/IAVI-Report-Volume-19-Issue-3.a…

See More

Why is curing HIV such a daunting task? Find out the answer to this and more in the latest issue of VAX!

Recently published research studies showcase progress in the development of vaccine candidates designed to induce powerful antibodies against HIV.